Christopher Zhong

Christopher Zhong is an associate in the firm’s Technology and Life Sciences groups.

Christopher represents biotechnology, pharmaceutical, diagnostic, and medical device companies in connection with their intellectual property, M&A, and commercial transactions.

Christopher’s representative transactions include:

• a China based pharmaceutical company in its license and collaboration agreement with Gilead
• Harbour BioMed in its license agreement with Otsuka Pharmaceutical
• Harbour BioMed in its collaboration agreement with AstraZeneca
• Duality Biologics (Suzhou) Co. Ltd. in its exclusive license agreement with Avenzo Therapeutics
• Velavigo in its exclusive license and option agreement with Avenzo Therapeutics
• Akamis Bio in its license agreement with Xuanzhu Biopharma
• Multitude Therapeutics in its license agreement with Adcendo ApS
• Vesalius Therapeutics in its collaboration agreement with GSK
• Flagship Pioneering in its collaboration agreement with GSK
• Duality Biologics (Suzhou) Co. Ltd. in its exclusive option agreement with GSK
• Ollin Biosciences in its option agreement with a China based pharmaceutical company
• Huadong Medicine Co, Ltd in its license agreement with IMBiologics
• Mariana Oncology in its acquisition agreement with Novartis
• Orum Therapeutics in its license and option agreement with Vertex Pharmaceuticals
• WuXi AppTec in its license agreement with Erasca
• KBP Biosciences in its license agreement with Novo Nordisk
• C4 Therapeutics in its license agreement with Betta Pharmaceuticals
• Celexor Bio in its license agreement with Inmagene Biopharmaceutical
• Duality Biologics (Suzhou) Co. Ltd. in its license and collaboration agreement with BeiGene
• Aktis Oncology in its collaboration agreement with Eli Lilly
• Graviton Bioscience Corporation in its collaboration and license agreement with Ovid Therapeutics, Inc.
• Duality Biologics (Suzhou) Co. Ltd. in its license and collaboration agreements with BioNTech SE
• Eterna Therapeutics, Inc. in its license agreement with Factor Bioscience Inc.
• Sichuan Kelun-Biotech Biopharmaceutical in its license and collaboration agreement with Merck
• Biosion USA, Inc. in its research and collaboration agreement with ImmunoGen, Inc.
• Entrada Therapeutics, Inc. in its collaboration and license agreement with Vertex Pharmaceuticals Incorporated
• Oak Hill Bio Ltd in its license agreement with Shire Human Genetic Therapies, Inc.
• Envisagenics, Inc. in its collaboration agreement with Bristol-Myers Squibb Company
• Bain Capital, LP in its JV investment in Areteia Therapeutics, Inc.
• Seagen Inc. in its collaboration and license agreement with Genzyme Corporation
• Ikena Oncology, Inc. in its collaboration agreement with Astrazeneca
• bluebird bio, Inc. in its license agreement with Resilience Boston, Inc.
• Absci Corporation in its collaboration agreement with Merck Sharp & Dohme Corp.
• Numerous biotech startups in commercial services agreements and supply agreements
• Numerous biotech startups in obtaining licenses from various universities and institutions
• A public company in issuing of $1 billion unsecured notes in an underwritten public offering*
• A pharmaceutical company in obtaining $100 million in secured term loans*
• A private equity firm in connection with multiple leveraged buyouts of companies in the healthcare, manufacturing, and high-tech industries*

*Denotes experience prior to joining Goodwin.

Prior to joining Goodwin, Christopher was at another leading international law firm, where he focused on representing pharmaceutical companies in financing and capital markets transactions and other general corporate matters.